Skip to content

Homeopathic medicines for dry eye disease

Efficacy of individualized homoeopathic medicines in improving symptoms of dry eye disease in adults: A double-blind, randomized, placebo-controlled trial - NIL

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064365
Enrollment
50
Registered
2024-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H162- Keratoconjunctivitis

Interventions

Intervention1: Individualized homoeopathic medicines in centesimal potencies plus concomitant care: The recommended homoeopathic medications will be administered in centesimal potencies (cH) as part
dosage and repetition depending upon the individual requirement of the cases. Patients will be advised to refrain from handling the globules or from eating, drinking, smoking or brushing teeth within

Sponsors

D. N. De Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals with an ocular surface disease index score (OSDI) 13 to 32(mild to moderate) and a Schirmer-1 test wetness of less than 15 millimeters. 2. Individuals who are 18 to 65 years old. 3. Patients of either gender or transgender. 4. Participants having prior experience or knowledge of the treatment; e.g., primed to expect ‘homoeopathic aggravation’ and available treatment options for the disease conditions, intimated through Patient Information Sheet.

Exclusion criteria

Exclusion criteria: 1. Individuals with OSDI score more than 32 (severe). 2. Those who have had eye surgery or trauma during the last three months. 3. Individuals who decline to provide written informed consent. 4. Patients suffering from various ocular disorders, such as glaucoma or keratitis. 5. A patient whose systemic disorders are the cause of their DED. 6. Women who are breastfeeding or pregnant or in puerperium. 7. Those suffering from any type of autoimmune condition, such as Sjogren syndrome, SLE, etc. 8. Persons with simultaneous participation in any other clinical trial. 9. Vulnerable population- Unconscious, non-ambulatory, too sick for consultation, differently abled, terminally ill or critically ill patients, mentally incompetent people. 10. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure. 11. Tobacco chewing and/or smoking, alcoholism and/or any other form(s) of substance abuse and/or dependence. 12. Self-reported immune-compromised state AIDS, Hepatitis, etc. 13. A person with uncontrolled diabetes or any other uncontrolled systemic disorders. 14. A patient receiving continuous homoeopathic treatment for any other chronic illness.

Design outcomes

Primary

MeasureTime frame
Ocular Surface Disease Index (OSDI) scoresTimepoint: Baseline, every month, up to 3 months

Secondary

MeasureTime frame
Measure Yourself Medical Outcome Profile (MYMOP-2) questionnaireTimepoint: Baseline, every month, up to 3 months;Schirmer-1 test scores (without anaesthesia)Timepoint: Baseline, every month, up to 3 months

Countries

India

Contacts

Public ContactDr Subhasish Ganguly

D. N. De Homoeopathic Medical College and Hospital

dr.subhasish67@gmail.com8017272982

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026